Bill Fleming’s career spans over 25 years in a broad range of finance positions.

Holding a Law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies, large blue chips and the biotech arena.

Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation.

Joining Ultromics in February 2018, Bill brings with him extensive experience in life sciences and technology sectors and is Chairman and Non-Executive Director at the leading life sciences network, OBN.

Bill Fleming